7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Motor unit number index (MUNIX) loss of 50% occurs in half the time of 50% functional loss according to the D50 disease progression model of ALS

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Capturing disease progression in amyotrophic lateral sclerosis (ALS) is challenging and refinement of progression markers is urgently needed. This study introduces new motor unit number index (MUNIX), motor unit size index (MUSIX) and compound muscle action potential (CMAP) parameters called M50, MUSIX200 and CMAP50. M50 and CMAP50 indicate the time in months from symptom onset an ALS patient needs to lose 50% of MUNIX or CMAP in relation to the mean values of controls. MUSIX200 represents the time in months until doubling of the mean MUSIX of controls. We used MUNIX parameters of Musculi abductor pollicis brevis (APB), abductor digiti minimi (ADM) and tibialis anterior (TA) of 222 ALS patients. Embedded in the D50 disease progression model, disease aggressiveness and accumulation were analyzed separately. M50, CMAP50 and MUSIX200 significantly differed among disease aggressiveness subgroups (p < 0.001) regardless of disease accumulation. ALS patients with a low M50 had a significantly shorter survival compared to high M50 (median 32 versus 74 months). M50 preceded the loss of global function (median of about 14 months). M50, CMAP50 and MUSIX200 characterize the disease course in ALS in a new way and may be applied as early measures of disease progression.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Amyotrophic lateral sclerosis

          Amyotrophic lateral sclerosis is characterised by the progressive loss of motor neurons in the brain and spinal cord. This neurodegenerative syndrome shares pathobiological features with frontotemporal dementia and, indeed, many patients show features of both diseases. Many different genes and pathophysiological processes contribute to the disease, and it will be necessary to understand this heterogeneity to find effective treatments. In this Seminar, we discuss clinical and diagnostic approaches as well as scientific advances in the research fields of genetics, disease modelling, biomarkers, and therapeutic strategies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

            The ALS Functional Rating Scale (ALSFRS) is a validated rating instrument for monitoring the progression of disability in patients with amyotrophic lateral sclerosis (ALS). One weakness of the ALSFRS as originally designed was that it granted disproportionate weighting to limb and bulbar, as compared to respiratory, dysfunction. We have now validated a revised version of the ALSFRS, which incorporates additional assessments of dyspnea, orthopnea, and the need for ventilatory support. The Revised ALSFRS (ALSFRS-R) retains the properties of the original scale and shows strong internal consistency and construct validity. ALSFRS-R scores correlate significantly with quality of life as measured by the Sickness Impact Profile, indicating that the quality of function is a strong determinant of quality of life in ALS.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Amyotrophic lateral sclerosis: a clinical review

              Abstract Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily the motor system, but in which extra‐motor manifestations are increasingly recognized. The loss of upper and lower motor neurons in the motor cortex, the brain stem nuclei and the anterior horn of the spinal cord gives rise to progressive muscle weakness and wasting. ALS often has a focal onset but subsequently spreads to different body regions, where failure of respiratory muscles typically limits survival to 2–5 years after disease onset. In up to 50% of cases, there are extra‐motor manifestations such as changes in behaviour, executive dysfunction and language problems. In 10%–15% of patients, these problems are severe enough to meet the clinical criteria of frontotemporal dementia (FTD). In 10% of ALS patients, the family history suggests an autosomal dominant inheritance pattern. The remaining 90% have no affected family members and are classified as sporadic ALS. The causes of ALS appear to be heterogeneous and are only partially understood. To date, more than 20 genes have been associated with ALS. The most common genetic cause is a hexanucleotide repeat expansion in the C9orf72 gene, responsible for 30%–50% of familial ALS and 7% of sporadic ALS. These expansions are also a frequent cause of frontotemporal dementia, emphasizing the molecular overlap between ALS and FTD. To this day there is no cure or effective treatment for ALS and the cornerstone of treatment remains multidisciplinary care, including nutritional and respiratory support and symptom management. In this review, different aspects of ALS are discussed, including epidemiology, aetiology, pathogenesis, clinical features, differential diagnosis, investigations, treatment and future prospects.
                Bookmark

                Author and article information

                Contributors
                annekathrin.roediger@med.uni-jena.de
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                9 March 2023
                9 March 2023
                2023
                : 13
                : 3981
                Affiliations
                [1 ]GRID grid.9613.d, ISNI 0000 0001 1939 2794, Department of Neurology, Jena University Hospital, , Friedrich Schiller University, ; Am Klinikum 1, 07747 Jena, Germany
                [2 ]GRID grid.275559.9, ISNI 0000 0000 8517 6224, Center for Healthy Ageing, , Jena University Hospital, ; Jena, Germany
                [3 ]GRID grid.4562.5, ISNI 0000 0001 0057 2672, Precision Neurology, , University of Lübeck, ; Lübeck, Germany
                [4 ]GRID grid.4562.5, ISNI 0000 0001 0057 2672, Cluster of Excellence Precision Medicine in Inflammation, , University of Lübeck, ; Lübeck, Germany
                Article
                30871
                10.1038/s41598-023-30871-x
                9998642
                36894607
                fc813f11-6539-48ca-8701-f65c476a60ac
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 26 September 2022
                : 2 March 2023
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100001659, Deutsche Forschungsgemeinschaft;
                Award ID: 413668513
                Award ID: EXC2167
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100010275, Deutsche Gesellschaft für Muskelkranke;
                Funded by: FundRef http://dx.doi.org/10.13039/501100000406, Motor Neurone Disease Association;
                Funded by: Interdisciplinary Center of Clinical Research of the Medical Faculty Jena
                Funded by: FundRef http://dx.doi.org/10.13039/501100002347, Bundesministerium für Bildung und Forschung;
                Award ID: 01ED1202B
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100017732, E-Rare;
                Award ID: 01GM1304
                Award Recipient :
                Funded by: Boris Canessa foundation
                Funded by: Universitätsklinikum Jena (8979)
                Categories
                Article
                Custom metadata
                © The Author(s) 2023

                Uncategorized
                motor neuron disease,amyotrophic lateral sclerosis,neurodegeneration,biomarkers
                Uncategorized
                motor neuron disease, amyotrophic lateral sclerosis, neurodegeneration, biomarkers

                Comments

                Comment on this article